In Week of Mar 28, 2026, Venus Remedies Ltd (Pharmaceuticals - I V Fluids) is outperforming Nifty 500 with +21.1% relative strength. Fundamentals: Average.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Elimination of ₹94.15L net worth erosion in Venus Pharma GmbH
“Management expects subsidiary's financial position to improve and stabilize by end of FY26 with revival strategies”
What: PAT margin expansion from 10.44% to 11.08% (Q3 FY25 level)
“Current margin improvement from 11.21% to 16.06% OPM shows positive trend”
What: Interest cost savings vs industry peers with debt
“Interest costs negligible at ₹0.01 cr reflecting debt-free status”
Earnings deceleration risks from management commentary
Trigger: Competitive pricing pressure or input cost increase
Impact: -838 bps margin impact
Management view: Not directly addressed but historical data shows pronounced volatility in earnings quality
Monitor: Quarterly PAT margin trend
Trigger: Extended payment terms with suppliers
Impact: -150 bps margin impact
Management view: Not directly addressed in available materials
Monitor: Trade payables to revenue ratio
Key quotes from recent conference calls
“Management expects the subsidiary's financial position to improve and stabilize by the end of the financial year 2025-26, with proposed financial support and revival strategies. — Management”
“Operating profit excluding other income reached ₹30.96 crores with a margin of 16.06%, marking a significant improvement from Q1 FY26's 11.21% but still trailing the 18.34% gross margin recorded in Q4 FY25. — Management”
“Interest costs were negligible at ₹0.01 crores, reflecting the company's virtually debt-free status. — Management”
Forward-looking targets from management for NEXT_2_4_QUARTERS
Key Milestones
• German subsidiary stabilization by FY26 end
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +2% | +2% | Stable |
| PAT (Net Profit) | +30% | +3% | Stable |
| OPM | 21.0% | +1100 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Venus Remedies Ltd's latest quarterly results (Dec 2025) show
Venus Remedies Ltd's profit is growing with an stable trend.
Venus Remedies Ltd's revenue growth trend is stable.
Venus Remedies Ltd's operating margin is volatile.
Venus Remedies Ltd's long-term compounding rates
Venus Remedies Ltd's earnings growth is stable with mixed signals on a sequential basis.
Venus Remedies Ltd's trailing twelve month (TTM) performance
Venus Remedies Ltd appears slightly undervalued based on our fair value analysis.
Venus Remedies Ltd's current PE ratio is 15.1x.
Venus Remedies Ltd's current PE is 15.1x.
Venus Remedies Ltd's price-to-book ratio is 1.9x.
Venus Remedies Ltd is rated Average with a fundamental score of 55.2/100. This score is calculated from objective financial metrics
Venus Remedies Ltd has a debt-to-equity ratio of N/A.
Venus Remedies Ltd's return ratios over recent years
Venus Remedies Ltd's operating cash flow is positive (FY2025).
Venus Remedies Ltd currently does not pay a significant dividend (yield 0.00%).
Venus Remedies Ltd's shareholding pattern (Dec 2025)
Venus Remedies Ltd's promoter holding has remained stable recently.
Venus Remedies Ltd has been outperforming Nifty 500 for 3 consecutive weeks, indicating early-stage outperformance.
Venus Remedies Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Venus Remedies Ltd has 3 key growth catalysts identified from recent earnings analysis
Venus Remedies Ltd has 2 key risks worth monitoring
In Q3 FY26, Venus Remedies Ltd's management highlighted
Venus Remedies Ltd's management has provided the following forward guidance for NEXT_2_4_QUARTERS
Based on quantitative research signals, here is why Venus Remedies Ltd may be worth studying
Venus Remedies Ltd investment thesis summary:
Venus Remedies Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
